IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
4.365
-0.855 (-16.38%)
At close: Jun 5, 2026, 4:00 PM EDT
4.158
-0.207 (-4.75%)
After-hours: Jun 5, 2026, 7:44 PM EDT
IceCure Medical Revenue
IceCure Medical had revenue of $911.00K in the quarter ending March 31, 2026, with 25.66% growth. This brings the company's revenue in the last twelve months to $3.57M, up 8.92% year-over-year. In the year 2025, IceCure Medical had annual revenue of $3.38M with 2.67% growth.
Revenue (ttm)
$3.57M
Revenue Growth
+8.92%
P/S Ratio
3.31
Revenue / Employee
$51,667
Employees
69
Market Cap
11.81M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.38M | 88.00K | 2.67% |
| Dec 31, 2024 | 3.29M | 62.00K | 1.92% |
| Dec 31, 2023 | 3.23M | 144.00K | 4.67% |
| Dec 31, 2022 | 3.09M | -1.05M | -25.45% |
| Dec 31, 2021 | 4.14M | 270.00K | 6.98% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| IRIDEX | 52.58M |
| Trinity Biotech | 43.79M |
| Lifeward | 20.92M |
| Vivos Therapeutics | 19.57M |
| Tenon Medical | 4.60M |
| VolitionRx | 2.47M |
| Sintx Technologies | 1.03M |
| Nexalin Technology | 275.58K |
ICCM News
- 2 days ago - Icecure Medical Ltd trading halted, news pending - TheFly
- 4 days ago - IceCure Medical implements 1-for-30 reverse share split for Nasdaq compliance - TheFly
- 4 days ago - IceCure Medical Announces 1-for-30 Reverse Share Split to Support Nasdaq Compliance - PRNewsWire
- 18 days ago - IceCure's ProSense® Reports Nearly 90% Recurrence-Free Rate for Cryoablation of Kidney Cancer: Data Presented at ECIO 2026 and First-Ever Breast Cryoablation Master Class Overbooked - PRNewsWire
- 23 days ago - IceCure Medical price target lowered to $1 from $3 at Maxim - TheFly
- 24 days ago - IceCure Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement - PRNewsWire
- 25 days ago - IceCure Medical reports Q1 EPS (6c) vs. (6c) last year - TheFly
- 25 days ago - IceCure Medical Earnings Call Transcript: Q1 2026 - Transcripts